Table 1.
Patient demographics.
Gender | Age | Dx | Medication | CPZ equivalent | IQ | AHRS score pre-Sess.2 | AHRS score post-Sess. 2 | AHRS score pre-Sess. 4 | AHRS score post-Sess. 4 | |
---|---|---|---|---|---|---|---|---|---|---|
1 | M | 55 | PSz | Abilify | 166.7 | 105 | 20 | 0 | 0 | 0 |
2 | F | 33 | PSz | Clozapine | 250 | 91 | 26 | 23 | 24 | 28 |
3 | M | 51 | PSz | Abilify | 333.4 | 104 | 32 | 24 | 27 | 19 |
4 | M | 35 | SAD | Clozapine | 150 | 112 | 26 | 24 | 23 | 26 |
5 | M | 55 | PSz | Olanzapine | 300 | 91 | 11 | 17 | 26 | 17 |
6 | M | 30 | PSz | Clozapine | 200 | 90 | 30 | 25 | 33 | 31 |
7 | M | 38 | PSz | Risperdal | 200 | 91 | 17 | 0 | 27 | 27 |
8 | M | 50 | SAD | Clozapine | 150 | 106 | 19 | 0 | 29 | 9 |
9 | M | 35 | Sz | NA | NA | 89 | 21 | 1 | NA | NA |
10 | M | 55 | SAD | Ziprasodone | 900 | 75 | 10 | 0 | 0 | 0 |
PSz = Paranoid schizophrenia, SAD = Schizoaffective disorder, Sz = Schizophrenia.
Medication and dosage did not change for any patient throughout the duration of the study.